We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi’s and Regeneron’s Libtayo Earns CHMP Recommendation for Two Forms of Advanced Cancer
Sanofi’s and Regeneron’s Libtayo Earns CHMP Recommendation for Two Forms of Advanced Cancer
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has voiced support for approving Sanofi’s and Regeneron’s monoclonal antibody Libtayo (cemiplimab) for advanced nonsmall-cell lung cancer (NSCLC) and advanced basal cell carcinoma.